# EASD diabetes congress in Milan > Live situation record from CLSTR: https://clstr.news/situations/easd-diabetes-congress-in-milan > Updated: 2026-10-03T09:38:51.000Z. Sources: 49. Developments: 3. The 62nd Congress of the European Association for the Study of Diabetes (EASD) in Milan highlighted significant advancements in diabetes management, screening, and therapeutic guidelines. Clinical discussions centered on the efficacy of semaglutide, which has received a recommendation 1A in the ESC 2026 Guidelines for patients with diabetes and kidney disease. Data presented at the congress confirmed semaglutide reduces major cardiovascular events by 26%, non-fatal strokes by 39%, and composite renal risk by 24%, while also improving functional capacity by 13%. Technological innovation remains a central theme. While previous discussions focused on AI-driven vocal pattern analysis for screening, the 2026 congress has expanded into automated insulin delivery. Companies SiBionics and PharmaSens are presenting the “niia signature,” an investigational wearable patch designed to integrate continuous glucose monitoring (CGM), insulin delivery, and an automated glucose control algorithm into a single unit. Research is also exploring multimodal sensing, such as continuous ketone monitoring, to improve metabolic control. Public outreach has also increased, with “off-congress” events moving research into museums and public squares through free glucose screenings and citizen science workshops. Regarding pregnancy safety, a meta-analysis of over 43,000 women found no significant association between GLP-1 receptor agonist exposure and risks such as preterm birth, fetal death, or pre-eclampsia, though researchers noted a 31% frequency of early pregnancy loss among exposed women and cautioned that data limitations make definitive conclusions difficult. On a policy level, the European Commission launched the first EU Screening Week to encourage early detection of cardiovascular risk factors. ## Claims - A metanalysis of over 43,000 women found no significant association between GLP-1 receptor agonist exposure and risks of preterm birth, fetal death, or pre-eclampsia. (disputed) - A metanalysis reported early pregnancy loss was more frequent at 31% among women exposed to GLP-1 agonists, though authors noted data limitations. (disputed) - The 62nd EASD Congress is being held in Milan from September 28 to October 2. (corroborated by 11 sources) - AI models can identify signs of type 2 diabetes by analyzing 20-second voice recordings. (corroborated by 10 sources) - Semaglutide has demonstrated a 26% reduction in major cardiovascular events and a 39% reduction in non-fatal strokes. (corroborated by 5 sources) - Semaglutide is positioned in recommendation 1A in the ESC 2026 Guidelines for improving cardiovascular outcomes in patients with diabetes and kidney disease. (corroborated by 5 sources) - Semaglutide has shown a 24% reduction in composite renal risk and a 13% improvement in functional capacity. (corroborated by 4 sources) - New EASD guidelines suggest extending continuous glucose monitoring (CGM) to all adults with type 2 diabetes, regardless of insulin treatment. (single source) - The 2026 ADA/EASD Consensus Report moves toward early and intensive treatment for diabetes. (single source) - In 2025, 42% of new type 1 diabetes cases globally will involve children and adolescents aged 0 to 19. (single source) - The number of people living with diabetes is projected to rise from 9.4 million in 2025 to 12.1 million by 2049. (single source) - 89% of healthcare professionals interviewed believe CGM helps assess treatment adherence between appointments. (single source) ## Timeline ### 2026-10-03: EASD 2026 in Milan showcases diabetes research and new medical technologies At the EASD 2026 congress in Milan, researchers and companies are showcasing advancements in diabetes care, including public health screenings and integrated wearable devices for automated insulin delivery. 9 sources. https://clstr.news/cluster/easd-2026-in-milan-showcases-diabetes-research-and-new-medical-technologies ### 2026-09-29: EASD Congress highlights semaglutide benefits and AI diabetes screening At the EASD Congress in Milan, experts highlighted semaglutide's cardiovascular benefits, new AI voice-based diabetes screening, and the importance of early cardiovascular risk detection in the EU. 39 sources. https://clstr.news/cluster/ai-voice-analysis-shows-potential-for-rapid-type-2-diabetes-screening ### 2026-09-25: Milan to host EASD diabetes congress and public health events Milan hosts the 62nd EASD Congress from Sept 28 to Oct 2, featuring public health initiatives including free screenings, a 5K run, and awareness events to promote diabetes prevention. 4 sources. https://clstr.news/cluster/milan-to-host-easd-diabetes-congress-and-public-health-events --- Cite as: EASD diabetes congress in Milan. CLSTR, https://clstr.news/situations/easd-diabetes-congress-in-milan